UBS reiterates Buy on Protagonist Therapeutics stock citing Mimrylo launch progress
Covered in this story
What has happened since
- Protagonist Therapeutics Inc is down 6.6% since this was published, 11 days ago.
Price move measured from the close nearest publication to the latest quote.
Tracked from this story
UBS’s $184 target on $PTGX is on the record and being tracked to Nov 2027 (12-month default), scored on the close that day.
UBS’s track record →Call it yourself
No member calls on $PTGX yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Protagonist Therapeutics Inc →Summary aggregated from Investing.com's public RSS feed. The full reporting belongs to Investing.com — please read it on their site.